ESMO: BMS’s Opdivo Edges Merck & Co’s Keytruda In First-Line Advanced Gastroesophageal Cancers
Competition Will Be Fierce Between Checkpoint Inhibitors
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
